Rani Therapeutics Holdings (RANI) Other Operating Expenses (2020 - 2024)
Rani Therapeutics Holdings (RANI) posted Other Operating Expenses of $3.7 million for Q4 2024, up 110.92% on a QoQ basis from -$34.0 million in Q4 2020.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Other Operating Expenses (2020 - 2024) Analysis & Trends
Rani Therapeutics Holdings has reported Other Operating Expenses for 2 years, with the latest figure at $3.7 million in Q4 2024.
- On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $3.7 million in Q4 2024; TTM through Sep 2025 was $3.7 million, a N/A change from a year earlier, with the FY2024 full-year figure at $3.7 million, changed N/A from the prior year.
- Other Operating Expenses was $3.7 million for Q4 2024 at Rani Therapeutics Holdings, up from -$34.0 million in the prior quarter.
- The five-year high for Other Operating Expenses was $3.7 million in Q4 2024, with the low at -$34.0 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - |